Lys178
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys178  -  RhoGDI alpha (human)

Site Information
ARGsYsIkSRFTDDD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3669184

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 ) , modification-specific antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
leukemia ( 4 , 5 ) , chronic myelogenous leukemia ( 4 , 5 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on RhoGDI alpha:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
cytoskeletal reorganization ( 1 )
Inhibit interaction with:
RHOA (human) ( 1 )

References 

1

Kuhlmann N, et al. (2016) Structural and Mechanistic Insights into the Regulation of the Fundamental Rho Regulator RhoGDIα by Lysine Acetylation. J Biol Chem 291, 5484-99
26719334   Curated Info

2

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

3

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

4

Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Moritz A (2010) CST Curation Set: 9920; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

7

Li Y (2006) CST Curation Set: 2113; Year: 2006; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info